Navigation Links
Ridge Diagnostics, Inc. CEO to Speak at Neurotech Investing and Partnering Conference
Date:5/5/2011

SAN DIEGO, May 5, 2011 /PRNewswire/ -- Ridge Diagnostics, Inc., a neurodiagnostic company, announced that Lonna J. Williams, CEO will speak at the 6th Annual Neurotech Investing and Partnering Conference to be held in San Francisco, CA at the St. Regis Hotel on May 9th and 10th.  

Ms. Williams, a clinical diagnostics industry veteran, will participate on a panel entitled "Next Generation Psychiatry" lead by Dr. Manuel Lopez-Figueroa, Vice President, Bay City Capital. The panel will discuss the most promising next generation diagnostics, devices and treatments for neuropsychiatric disorders such as depression, schizophrenia, anxiety, addiction and others.

Ridge Diagnostics develops and sells blood tests which aid in the diagnosis and management of clinical depression or Major Depressive Disorder.  For the first time, a blood test provides clinicians and patients with objective, biologically based, diagnostic information to manage and treat this disorder.    Blood test results are intended to augment the current tools used for neuropsychiatric diagnosis and patient management.  Additional tests are in development for antidepressant efficacy monitoring and adolescent depression.

Ridge Diagnostics, Inc. Ridge Diagnostics is a neurodiagnostic company developing and marketing blood-based tests to diagnose and monitor neuropsychiatric disorders.  Ridge has commercialized the first-in-class, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD).   The portfolio of neurodiagnostic blood tests are based on a proprietary Human Biomarker Library and Hyper-Mapping technology.  The testing services are provided by the Ridge owned CLIA laboratory. The company is located in San Diego, CA and Research Triangle Park, NC.   www.ridgedx.com

Neurotech Investing and Partnering Conference. The premier partnering and investing conference where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry. Find out about next generation drugs, devices and diagnostics for Alzheimer's, addiction, anxiety, depression, Huntington's, ALS, pain, sensory disorders, obesity, stroke, schizophrenia, sleep disorders, epilepsy, multiple sclerosis, traumatic brain injury, spinal cord injury, Parkinson's and more.


'/>"/>
SOURCE Ridge Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
2. Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
3. Breckenridge Pharmaceutical Enters Agreement with Oman Pharmaceutical Products Company LLC
4. BridgePoint Medical Names Industry Veteran as Chief Executive Officer
5. BridgePoint Medical Closes $9.1 Million Series C Financing
6. Sunridge Signs Distribution Agreement for Turkey
7. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
8. Sunridge Moves Forward to Open Company Owned Clinics
9. Rockbridge Growth Equity Leads Acquisition of Connect America, a Leading Direct to Consumer Provider of Personal Emergency Response Systems (PERS)
10. HeartWare Files PMA Application for FDA Approval of the HeartWare® Ventricular Assist System for a Bridge-to-Transplant Indication
11. Caliper Life Sciences to Acquire Cambridge Research & Instrumentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... AMSTERDAM , Feb. 27, 2017   ... AEX: PHIA), a global leader in health technology, ... and Drug Administration (FDA) to market its ElastQ ... EPIQ family of ultrasound systems. ElastQ Imaging enables ... stiffness, which is essential for the diagnosis of ...
(Date:2/27/2017)... 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... company focused on tissue protection, repair and regeneration, ... Co., Ltd., received a positive response from the ... design for RGN-137 to treat epidermolysis bullosa ("EB"). ... incorporates Thymosin beta 4 ("Tß4") as the active ...
(Date:2/27/2017)... 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: ... M.D., Ph.D., as President and Chief Executive Officer (CEO) and ... Dr. Craig succeeds Richard Love , interim President and ... of Directors.  Dr. Craig has over 20 years of experience ... and Europe . "On behalf ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... This is an ... world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house ... is the globally recognised standard that sets out requirements for the technical competence ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing a new ... B2B Sellers will now only pay for B.A.N.T. quality sales leads based on the ... said, “Given the new reality that B2B buyers are controlling the sales process via ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports improved ... study released today at the 1st Pan American Parkinson’s and Movement Disorders Congress. ... effective in improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao ...
(Date:2/24/2017)... ... 24, 2017 , ... HealthPostures, expert standing desk solution designer, ... built into the home office sit stand solution are bold colors, a new ... the benefits embedded in the TaskMate Go are available 24/7 through HealthPostures' online ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , The New Jersey ... as well as advocacy for the state and region‘s technology businesses, hosted their ... The Council's Innovation Forecast event highlights innovation throughout the region from small to ...
Breaking Medicine News(10 mins):